Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).
NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
11:45am, Friday, 12'th Sep 2025
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
11:26am, Friday, 12'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options
NEW YORK , Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsu
REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
05:08pm, Thursday, 11'th Sep 2025
REPL Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Sept. 11, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulator
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities la
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
08:45am, Thursday, 11'th Sep 2025
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
The lawsuit alleges Replimune overstated the IGNYTE trial's prospects despite known issues, leading the FDA to deem it inadequate and investors harmed.
NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
02:24pm, Wednesday, 10'th Sep 2025
SAN FRANCISCO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Su
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2
Investors can contact the law firm at no cost to learn more about recovering their losses
